Tehran, May 28, IRNA - Iranian research company, Ariatinagen, has produced a medicine named Tinagrast for cancer patients undergoing chemotherapy.Navid Mirqasemi, manager of the company, said Tinagrast helps patients overcome neutropenia and infections.
Neutropenia is a granulocyte disorder characterized by an abnormally low number of neutrophils. Neutrophils usually make up 50-70 percent of circulating white blood cells and serve as the primary defense against infections by destroying bacteria in the blood.
Hence, patients with neutropenia are more susceptible to bacterial infections and, without prompt medical attention, the condition may become life-threatening (neutropenic sepsis).
Neutropenia poses a serious threat to patients on chemotherapy, exposing them to infection and leading to delays in treatment and reductions in dose intensity.
Mirqasemi also said the drug reduces cancer patients pains, adding that it has been exported as a prefilled syringe.
Ariatinagen Company is a member of Golestan provinces Science and Technology Park.
By IRNA
The Iran Project is not responsible for the content of quoted articles.
